Cytomegalovirus surveillance after antiviral prophylaxis in CMV mismatched transplant patients: Does recurrent cytomegalovirus DNAemia impact patient survival?
Oscar A. Fernández‐García, Cristina Hernandez, Mark Robbins, Dima Kabbani, Karen Doucette, Carlos CerveraAbstract
Background
Cytomegalovirus (CMV) mismatched, donor IgG‐positive/recipient IgG‐negative, solid organ transplant recipients (SOTRs) are at high risk of CMV invasive disease. Post‐prophylaxis disease is an issue in this population. Some programs employ surveillance after prophylaxis (SAP) to limit the incidence of post‐prophylaxis disease.
Methods
This was a single‐center retrospective cohort study that included all CMV mismatched SOTRs from 2003 to 2017. Patients underwent SAP with weekly CMV plasma viral load for 12 weeks. The subjects were classified into three post‐prophylaxis DNAemia patterns: no DNAemia, one episode of DNAemia, and multiple episodes of DNAemia. We calculated the cumulative incidence of each DNAemia pattern. We also determined 5‐year mortality based on DNAemia pattern stratified by organ transplant type.
Results
Post‐prophylaxis recurrent DNAemia occurred in 63% of lung recipients and 32% of non‐lung recipients (p = .003). Tissue invasive CMV disease was diagnosed in 3% of the population and CMV syndrome was diagnosed in 33%. Recurrent DNAemia was not associated with 5‐year mortality.
Conclusion
In this cohort, undergoing SAP tissue invasive disease was uncommon and CMV DNAemia recurrence did not have an impact on long‐term mortality.